People: Neptune Technologies & Bioressources Inc (NEPT.O)

NEPT.O on Consolidated Issue listed on NASDAQ Capital Market

2.05USD
21 Nov 2014
Price Change (% chg)

$0.14 (+7.33%)
Prev Close
$1.91
Open
$1.98
Day's High
$2.10
Day's Low
$1.94
Volume
361,196
Avg. Vol
202,547
52-wk High
$3.61
52-wk Low
$1.11

Search Stocks

Summary

Name Age Since Current Position

Pierre Fitzgibbon

59 2014 Chairman of the Board

Andre Godin

2014 Interim President and Chief Executive Officer, Chief Financial Officer

Michel Timperio

2013 Senior Vice President of Sales - Global Sales

Wael Massrieh

Vice President - Scientific Affairs

Fotini Sampalis

2012 Chief Global Strategy Officer

Ronald Denis

2014 Director

Harlan Waksal

60 2012 Director

Valier Boivin

2013 Independent Director

Adrian Montgomery

2014 Independent Director

John Moretz

2014 Independent Director

Reed Tuckson

2013 Independent Director

Jerald Wenker

2014 Independent Director

John Ripplinger

IR Contact Officer

Biographies

Name Description

Pierre Fitzgibbon

Mr. Pierre Fitzgibbon is Chairman of the Board of Neptune Technologies & Bioressources Inc., Mr. Fitzgibbon formerly served as President and Chief Executive Officer of Atrium Innovations Inc., a leader in the development, manufacturing and marketing of added value products for the health and nutrition industry. Atrium was recently sold in a transaction valued at over $1.1 billion. Prior to joining Atrium, Mr. Fitzgibbon was Vice-Chairman of National Bank Financial and Senior Vice-President, Finance, Technology and Corporate Affairs at National Bank of Canada.

Andre Godin

Mr. Andre Godin C.A., is Interim President and Chief Executive Officer, Chief Financial Officer of Neptune Technologies & Bioressources Inc. Mr. Godin has a Bachelor in Administration and has been a Member of the Canadian Institute of Chartered Accountants since 1988. He has more than 10 years experience in the Biotech/Pharma industry as former President of a Dietary Supplement Corporation and as a Corporate Controller for a pharmaceutical Corporation in OTC products.

Michel Timperio

Mr. Michel Timperio is Senior Vice President of Sales - Global Sales of Neptune Technologies & Bioressources Inc. Mr. Michel Timperio obtained a Bachelor degree from Concordia University in 1980 and attended additionnal courses at l’ENAP (National Institute of Public Administration). Mr. Timperio was elected as Chairman of the Board of Neptune in 2000 until 2008. He joined Neptune as a full time employee in September 2010. Prior to joining the Neptune team, Mr. Timperio started his career with Amstrong World Industries as sales representative for Eastern Canada and subsequently with Reicchold Chemicals as regional sales manager in 1982. After earning a young entrepreur loan and scholarship, he started his own distribution business, Specgraphix/Unic in 1985 specializing in the distribution of printing raw material products. During his business endeavours he was the recipient of many sales recognition awards as top sales executives and was also elected as alderman seating on the executive council of one of the largest Montreal suburb, in the city of Longueuil. In 1987, He hosted the first socioeconomic summit of one of the largest administrative region in the province of Québec.

Wael Massrieh

Mr. Wael Massrieh is a Vice President - Scientific Affairs of Neptune Technologies & Bioressources Inc., Mr. Wael Massrieh completed his Bachelors of Science in Microbiology and Immunology at McGill University where he then pursued his Doctorate in Medicine, in the division of Experimental. His research on pro-inflammatory cytokines and regulation of transcription factors during premature labor research is published multiple times in peer reviewed publication. In addition to completing a “Mini-MBA” program, certified by the International Pharmaceutical Academy in September 2011, he is a member of the Project Management Institute and is completing the Project Management Professional (PMP®) Certification. Prior to joining Neptune, he held the position of Director of R&D at BIOTONIX INC, where he steered and advanced research on body posture and psychology. Mr. Wael Massrieh joined Neptune in 2007 and held the position of Director of R&D and is currently the Vice President of Scientific affairs.

Fotini Sampalis

Dr. Fotini Sampalis, M.D., Ph.D., is Chief Global Strategy Officer of Neptune Technologies & Bioressources Inc. Dr. Sampalis is an Oncology Surgeon, trained in Physiology at McGill University, Medicine at the University of Patras (Greece), Dermatology at Göttingen University (Germany) and Marselisborg University (Denmark), Pediatric, General and Oncology Surgery at the University of Athens (Greece), graduate training (PhD) in Surgical Research at the University of Athens and a second PhD in Epidemiology and Experimental Surgery at McGill University. She has received several international scholarships and awards for her work on the clinical implementation of retinols skin and breast cancer including the Helen Hutchison Award for geriatric medicine. Her work on Scintimammography resulted in her appointment at the International Educational Speakers Bureau, the Canadian and U.S. Faculty of Medical Speakers for Breast Imaging. As an international scholar she leads the development and implementation of innovative micro-invasive and stereotactic robotic surgical techniques for breast cancer, for which a USA and Canadian patent application has been filed. She is a member of the American Association of Naturopathic Medicine. Dr. Sampalis has published in multiple peer reviewed publications.

Ronald Denis

Dr. Ronald Denis is Director of Neptune Technologies & Bioressources Inc. Dr. Ronald Denis has been Chief of Surgery and director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal since 1997. Since 1987, Dr. Denis has also been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Harlan Waksal

Dr. Harlan W. Waksal, M.D., is Director of Neptune Technologies & Bioressources Inc., since May 23, 2012. He is a retired physician. Dr. Waksal is the Vice-President, Business and Scientific Affairs at Acasti Pharma Inc. (“Acasti”), the Corporation’s subsidiary. He received his B.A. from Oberlin College and M.D. from Tufts University School of Medicine, and his post graduate training in Internal Medicine and in Pathology. In addition, he did research in immunology at the Weizmann Institute of Science. Dr. Waksal was a founder of Imclone Systems Incorporated; a New York based pharmaceutical company specializing in developing new treatment for various forms of cancer. He served as the Chief Operating Officer and member of the Board of Directors from 1986 until 2001 and as President/CEO from 2001 until 2002. During his tenure, he was responsible for building the scientific and operation infrastructure of the company. Dr. Waksal is the author of over 50 scientific publications and has been the author of multiple patents and patent applications. His current activities are focused on managing various real estate developments and serving on select Board of Directors. Dr. Waksal currently serves on the Boards of the Oberlin College, Senesco Technologies, Inc. He also serves on the Advisory Board of Northern Rivers Funds.

Valier Boivin

Mr. Valier Boivin is an Independent Director of Neptune Technologies & Bioressources Inc., Mr. Valier Boivin holds a bachelor’s degree in Economic and Administrative Sciences (UQAC-1973), a master’s degree in Taxation (Université de Sherbrooke, 1978) and a law degree (Université de Montréal, 1985). Furthermore, he is a member of the “Barreau du Québec” since 1986 and the “Ordre des comptables agréés du Québec” since 1974. He held the position of Professor at the Université du Québec à Chicoutimi until 1978 and then joined the master’s degree in taxation program as Professor, at the Université de Sherbrooke until 1987. Founder (in 1987) of Boivin O’Neil, s.e.n.c., he practices business law. Specialized in Mergers & Acquisitions and corporate financing, he acts as legal and strategic counsel to many private and public companies. Since January 2009, he is President of the regional economic intervention fund, FIER Ville-Marie L.P. Mr. Boivin is also socially involved with various professional associations, non-profit organizations and charitable foundations.

Adrian Montgomery

Mr. Adrian Montgomery is an Independent Director of Neptune Technologies & Bioressources Inc., Mr. Montgomery is the Chief Investment Officer of Tuckamore Capital, a publicly-traded company that has invested approximately $700 million in successful private businesses since its inception in 2005. Prior to joining Tuckamore, he headed business development at Rogers Media Inc. Mr. Montgomery is a lawyer and member of the New York State Bar and currently serves on the boards of Epsilon Energy, a TSX-listed Company, and the Toronto East General Hospital Foundation.

John Moretz

Mr. John Moretz is an Independent Director of Neptune Technologies & Bioressources Inc., Mr. Moretz currently serves as Chief Executive Officer and President of Moretz Marketing LLC and is Managing Director for Kathy Ireland, LLC. In addition, he is the managing director for various real estate entities, including LaMoe, LLC and Moretz Mills, LLC. Mr. Moretz spent 39 years in the hosiery industry. He served as the Chairman and Chief Executive Officer of Gold Toe Moretz Holdings Corp. and its subsidiaries prior to its acquisition by Gildan Activewear Inc. in 2011. Mr. Moretz also founded Moretz Marketing in 1987 to create and manage lifestyle brands and create licensing opportunities.

Reed Tuckson

Dr. Reed V. Tuckson, M.D., has been appointed as an Independent Director of Neptune Technologies & Bioressources Inc., with effect from 5 November 2013. Dr. Tuckson is currently the Managing Director of Tuckson Health Connections, LLC, a health and medical care consulting business. Previously, he served a long tenure as Executive Vice President and Chief of Medical Affairs for UnitedHealth Group, a Fortune 25 health and wellbeing company, which includes the United States largest health insurer and the industry's most comprehensive health services company. Dr. Tuckson is a graduate of Howard University, Georgetown University School of Medicine, and the Hospital of the University of Pennsylvania's General Internal Medicine Residency and Fellowship Programs, where he was also a Robert Wood Johnson Foundation Clinical Scholar studying at the Wharton School of Business.

Jerald Wenker

Mr. Jerald J. Wenker is an Independent Director of Neptune Technologies & Bioressources Inc., Mr. Wenker is currently President and Chief Operating Officer of Dermalogica, a leading professional skin care company based in the United States. Previously, he was President of Ther-Rx Corporation, the branded division of KV Pharmaceuticals. Prior to Ther-Rx, Mr. Wenker worked at Abbott Laboratories for approximately 15 years where he held several executive roles in such areas as commercial and marketing management, strategic planning, licensing and new business development as well as new product development. Mr. Wenker holds a Master of Science in Marketing from Northwestern University’s J.L. Kellogg Graduate School of Management.

John Ripplinger

Basic Compensation

Options Compensation

Search Stocks